To hear about similar clinical trials, please enter your email below
Trial Title:
Predictive Value of Soluble CD146 in Glioblastoma Patients
NCT ID:
NCT06001281
Condition:
Glioblastoma
Conditions: Official terms:
Glioblastoma
Conditions: Keywords:
glioblastoma
CD146
bevacizumab
Study type:
Interventional
Study phase:
N/A
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Basic Science
Masking:
None (Open Label)
Intervention:
Intervention type:
Other
Intervention name:
plasma collection
Description:
Plasma samples will be prospectively collected at relevant time points during patient
treatment.
Arm group label:
plasma collection
Summary:
Glioblastoma is the most common malignant primary brain tumor with poor prognosis because
of its diffusive and infiltrative nature. The FDA approved the use of the anti-VEGF
antibody bevacizumab in recurrent GBM. However, resistance to this anti-angiogenic
reagent is frequent and fails to enhance patients' overall survival. The investigators
previously identified one novel mechanism responsible for bevacizumab-resistance in
CD146-positive glioblastoma (Joshkon et al. Acta Neuropathol Commun, 2022).
Now, the investigators objective is to prospectively monitor the soluble CD146 value in
plasma from patients treated by bevacizumab for recurrent glioblastoma.
The investigators will collect plasma at baseline, before the first bevacizumab
administration, before the second administration, at the time of first MRI evaluation and
at progression. Plasma CD146 value will be analyzed by ELISA.
The investigators expect to confirm the correlation between soluble CD146 value in plasma
and patient response to bevacizumab.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
-
- Adult patients with recurrent IDHwt glioblastoma
- Relapse after standard first line treatment (radio-chemotherapy)
- Candidate for bevacizumab treatment
- Able to be monitored by MRI
- KPS ≥ 60%
- Written signed consent form
Exclusion Criteria:
- Pregnancy or breast feeding
- Life expectancy less than 3 months
- Bevacizumab in first line treatment
- Other concomitant life-threatening disease
- Under legal protection
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Service de Neuro-oncologie
Address:
City:
Marseille
Zip:
13005
Country:
France
Status:
Recruiting
Contact:
Last name:
TABOURET Emeline
Phone:
0491385500
Phone ext:
33
Email:
emeline.tabouret@ap-hm.fr
Start date:
January 30, 2024
Completion date:
December 2026
Lead sponsor:
Agency:
Assistance Publique Hopitaux De Marseille
Agency class:
Other
Source:
Assistance Publique Hopitaux De Marseille
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06001281
